PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80036Procurent of xofluza (baloxavir marboxil) 40mg — Genentech Usa, Inc

Genentech Usa, Inc holds $136.1M across 34 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Genentech Usa, Inc

Recipient

Sep 29, 2027

PoP end

$37.5M

Obligated

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Genentech Usa, Inc — $90

Contract facts

Federal

Contract number75A50325F80036

Also listed as36F79723D0219-75A50325F80036

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentGenentech Usa, Inc

UEISA85BMHCTXK5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79723D0219

Place of performanceSOUTH SAN FRANCISCO, CA

PoP end (current)Sep 29, 2027

Obligated$37.5M

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS is a federal award for Aspr/Orm-Sns held by Genentech Usa, Inc. Estimated value $75M ($37.5M obligated). Current period of performance ends Sep 29, 2027. Last award drew 1 bidder. Place of performance: SOUTH SAN FRANCISCO, CA.

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Recompete timing

Public

● Expiring in 405 days

Current PoP ends Sep 29, 2027 (405 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Genentech Usa, Inc — $136.1M obligated across 34 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($136.1M) · all agencies

Department of Health and Human Services (HHS)$134.6M · 99%Department of Defense (DOD)$1.6M · 1%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325F80036?

75A50325F80036 (Procurent of xofluza (baloxavir marboxil) 40mg) is a Aspr/Orm-Sns award with an estimated value of $75M, currently held by Genentech Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80036?

Aspr/Orm-Sns awarded 75A50325F80036 to Genentech Usa, Inc.

Who is the incumbent on 75A50325F80036?

Genentech Usa, Inc is the incumbent with $136.1M across 34 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Genentech Usa, Inc’s 75A50325F80036 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Mar 17, 2026